Ground-breaking work creates novel oil-in-water nanoemulsions

3 Dec 2019

New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.

Particle Technology is an important discipline that underpins many industrial sectors, including biomedical applications, latex paints and coatings, engine oil additives, viscosity modifiers and emulsion stabilisation. Steve Armes, Professor of Polymer and Colloid Chemistry at the University of Sheffield, is one of the UK's leading experts in particle science and technology, with more than 30 years of research experience in this field. In particular, he designs a wide range of microscopic polymer particles on the nanoscale.

Ground-breaking work creates novel oil-in-water nanoemulsions

Professor Steve Armes said: "It is well known that oil and water do not mix. Similarly, the incorporation of oil droplets within inorganic crystals is highly counter-intuitive because there is a large difference in surface energy for these two components. Our new occlusion protocol, developed using the high-pressure LV-1 microfluidizer, has enabled either oil-soluble dyes or oil-dispersible hydrophobic nanoparticles to be incorporated for the first time within host crystals. This exciting new innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives for various commercial applications. In view of this, we have filed a preliminary patent application to protect the IP associated with our work.

Professor Ames added: “We are indebted to the excellent technical support provided by Analytik, which has enabled us to fully exploit the high-pressure LV-1 Microfluidizer for the production of well-defined nanoemulsions. We will be seeking their support and advice in the future as we seek to extend our studies to include water-in-oil nanoemulsions.”

The LV1 Microfluidizer is a high shear homogeniser which brings outstanding processing capabilities to samples as small as 1 mL. The LV1 has been designed to achieve operating pressures up to 30,000 psi for samples ranging from 1-6 mL. Using proprietary fixed-geometry interaction chamber technology, the LV1 is capable of processing a wide variety of fluids such as oil-in-water emulsions, solids-in-liquid suspensions, and cells, including the most difficult yeasts and plant cells, in as few as 1-2 passes. What's more, the process is repeatable and is guaranteed to scale up to pilot and/or production volumes.

Read More

Related news

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

15 Jan 2020

BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.

Read more 
Biogen to acquire novel clinical-stage asset from Pfizer

Biogen to acquire novel clinical-stage asset from Pfizer

14 Jan 2020

PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.

Read more 
French regulator agrees to partial resumption of Tellomak trial patient recruitment

French regulator agrees to partial resumption of Tellomak trial patient recruitment

14 Jan 2020

The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...

Read more 
Partnership formed to develop and commercialise ready-to-use medicine

Partnership formed to develop and commercialise ready-to-use medicine

13 Jan 2020

The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.

Read more 
ReadCoor to commercially launch spatial sequencing platform

ReadCoor to commercially launch spatial sequencing platform

10 Jan 2020

Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more 
NIH researchers discover new autoinflammatory disease

NIH researchers discover new autoinflammatory disease

3 Jan 2020

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Read more 
BioAscent scientists help identify potential new treatments for cancer

BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Read more 
NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina

NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina

13 Dec 2019

NEI-led study to test safety of treatment for a form of age-related macular degeneration that currently lacks treatment.

Read more 
Sanofi bolsters its immuno-oncology pipeline for $2.5B

Sanofi bolsters its immuno-oncology pipeline for $2.5B

6 Dec 2019

Lead asset THOR-707 being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations.

Read more